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“activated/exhausted” expression profile of B-DC apparently resulted from a more activated monocyte precursor.
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same DC product, and that less “activated/exhausted” DC could positively affect the outcome of immunotherapy.
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Dendritic cells (DC)-based immune-therapy (commonly
called “therapeutic vaccine”) has been reported as an inter-
esting approach to induce a control of plasma viral load (PVL)
in HIV positive (HIVþ) patients as well as an important tool
for deeper investigating the correlation of protection against
HIV infection in these patients.
Since the first published results [1e3], it appeared that not all
the immunized patients uniformly respond to the treatment,h Institute. Publishing services by Elsevier B.V. This is an open access article
.0/).
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factors that might affect the out-come of immunization, and the
definition of guide lines to appropriately choose individuals with
greatest chance to effectively respond to immune-therapy.
Genetics screening of HIVþ patients submitted to the first-
phase clinical trial of a French-Brazilian DC-based vaccine [3]
evidenced that polymorphisms in MBL2, NOS1, PARD3B and
CNOT1 genes were associated with a weak or transient
response (not significantly diminished PVL) observed in half
of 18 treated subjects [4e6].
The profile of “weak/transient” or “good” responder may
also depend on several factors, other than host genome, such
as the quality of DC obtained in vitro from patient's peripheral
blood monocytes, and the ability of patient's immune system to
be activated by the in vitro manipulated DC. Considering that
immune response of HIVþ individuals is greatly impaired by
HIV-1 infection itself, questions about the responsiveness to a
DC-based vaccine are strictly correlated with the ability of
each individual to counteract the infection.
In this context we considered that exploring DC gene
expression profile may be helpful for understanding genes or
pathways linking DC biology and a good response to immu-
notherapy, and finally for the selection of individuals that can
be benefit from this type of intervention.
Nowadays other 20 Brazilian HIVþ patients were enrolled
in the second-phase of Lu et al. clinical trial [3], and biologic
samples are becoming available for novel investigation.
All this considered and taken into account that the intrinsic
ability of each HIVþ individual to counteract HIV-1 results in a
different rate of immune cells activation [7,8] and consequently
in a different capacity of HIVþ to be responsive toward exog-
enous stimulation (i.e.: immunotherapy), we decided to study
differential expression of genes involved in host anti-HIV
response in available cells from 6 HIVþ patients included in
the phase-I/II clinical trial. To determine whether this expres-
sion profile is different among vaccinated individuals and if an
alteration of this profile could eventually be prejudicial to
immunotherapy, HIV restriction genes expression was evalu-
ated in different steps of monocytes-to-DC preparation ac-
cording to immunotherapy protocol [3] and correlated with DC
characteristics and functions, HIV restriction factors genetics,
and with clinical trial results.
2. Material and methods2.1. Patients
Table 1
Main characteristics of HIVþ subjects selected for the study.
ID Age/Sex PVL
(copies/ml; log10)
CD4þ count
(cells/ml)
CD8þ count
(cells/ml)
P1 40/M 21,420; 4.3 566 776
P2 35/M 38,295; 4.6 500 1100
P3 27/M 5003; 3.7 500 1139
P4 24/M 24,530; 4.4 569 868
P5 23/M 1342; 3.1 684 822
P6 39/M 1237; 3.1 500 1371
Abbreviations: M ¼ male; PVL ¼ plasma viral load; CD4þ ¼ CD4þ
T lymphocytes, CD8þ ¼ CD8þ T lymphocytes.Six HIV-1 positive Brazilian individuals were selected
within the subjects submitted to anti-HIV immunotherapy
clinical trial at the Laboratory of Medical Investigation/LIM-
56 (Faculty of Medicine, University of Sao Paulo, Brazil)
due to the availability of biologic material. All individuals
were males, adults (31.3 ± 7.6 years), classified as European-
derived according to an appropriate questionnaire [9,10],
proceeding from Sao Paulo city geographical area. They are
seropositive for at least 5 years, naïve for antiretroviral therapy
and without clinical AIDS or other chronic diseases, withblood CD4þ cells count >500 cells/ml, and PVL >3 log (1000
RNA copies/ml). Patients' main characteristics are summa-
rized in Table 1. Detailed PVL and CD4þ data collected
during treatment follow-up are reported in Supplementary
Table 1. Written informed consent was obtained according
to the protocol of “Hospital das Clinicas” Ethical Committee
(CAPPesq) (number 0791/09, 04 November 2009).2.2. Monocyte-derived dendritic cellsMonocyte-derived dendritic cells (DC) were obtained and
stimulated according to the protocol used in anti-HIV immu-
notherapy by Lu et al. [3]. Briefly, peripheral blood mono-
nuclear cells (PBMC), obtained by centrifugation over Ficoll-
Paque gradient, were distributed in 24-wells plates at 5  106/
well, and monocytes isolated by adherence and cultured in
AIM-V medium (Gibco, Life Technologies) containing 50 ng/
mL GM-CSF (Cell Genix) and 50 ng/mL IL-4 (Cell Genix).
Non-adherent PBMC were used for co-culture assays. On day
5, immature DC (iDC) were pulsed with alditrithiol-2 inacti-
vated HIV-1 (1  109 viral particles/30  106 cells) for 4 h
(4 h-DC), then cells were washed and DC “maturation”
cocktail (50 ng/mL IL-4, 50 ng/mL GM-CSF, 50 ng/mL
tumour necrosis factor (TNF), 10 ng/mL IL-1b, 100 ng/mL IL-
6) (Cell Genix) was added for further 10 (14 h-DC), 20 (24 h-
DC) or 44 h (48 h-DC). 48 h-DC represent the mature DC and
the final product of the manipulation. iDC and 48 h-DC were
analysed for dendritic cell differentiation and activation
markers by flow-cytometry. Viability of 48 h-DC was evalu-
ated. Cells were lysed for mRNA isolation and for gene
expression analysis at all the above-mentioned time-points
(monocytes, iDC, 4 h-, 14 h-, 24 h-, 48 h-DC).2.3. Virus isolation and expansionVirus isolation and expansion were performed according to
WHOeUNAIDS Guidelines [11] with minor modifications
[3]. Viral inactivation was made with Aldrithiol™-2 as
described elsewhere [12].2.4. RNA isolation and RT2 profiler PCR arrayTotal RNA was isolated using the RNAeasy mini kit
(Qiagen) and quantified using Nanodrop N-1000 (Agilent
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the RT2 PreAMP cDNA Synthesis Kit (Qiagen). Samples were
analysed for expression of 84 genes involved in host genome
anti-HIV response by RT2 Profiler PCR “Host Genome Anti-
HIV” Array (PAHS-051Y, Qiagen). Real-time PCR detection
was performed on ABI 7300 Real-Time PCR System (Applied
Biosystems). RT2 Profiler PCR Array data were analysed
using the comparative Ct method as proposed by Schmittgen
& Livak [13]. This method calculates differences in Ct data,
normalized for house-keeping genes (DCt), between two
samples as fold change/FC. Average Ct of 4 housekeeping
genes (b-actin/ACTB, b-2-microglobulin/B2M, glyceralde-
hyde-3-phosphate dehydrogenase/GAPDH, hypoxanthine
phosphoribosyl-transferase 1/HPRT1) for each individual was
used for normalization. Ct > 35 were excluded. Triplicates
were used for each analysis. Genes with two missing values
within the groups were excluded from analysis. Student's t-test
was used to calculate two-tail, equal variance p-values in each
triplicate. Quality controls confirmed the lack of DNA
contamination and were successfully tested for RNA quality
and PCR performance. Heatmaps and clustering were obtained
with R-projects packages “gplots”.2.5. RT-PCR with Taqman assaysNLRP3, CASP1 and IL18 genes were amplified with spe-
cific TaqMan Gene Expression Assays (Applied Biosystems)
using the ABI 7300 SDS platform (Applied Biosystems).
ACTB was the housekeeping gene used for normalization.
Relative quantitative expression was obtained using the
comparative Ct method as proposed by Schmittgen & Livak
[13]. Data was analysed by One-Way Anova and Bonferroni
post-test in GraphPad Prism software.2.6. Analysis of polymorphisms in HIV restriction factor
genesTwenty-two polymorphisms in 13 genes involved in HIV-1
host restriction genes (rs3736685 and rs2294367 in APO-
BEC3G, rs1719153 and rs1719134 in CCL4, rs2280789 and
rs2107538 in CCL5, D32 in CCR5, rs11212495 and rs7103534 in
CUL5, rs2234358 in CXCR6, rs10484554 and rs9264942 in
HLA-C, rs2069709 in IFNG, rs11884476 in PARD3B,
rs17762192 in PROX1, rs1801157 in SDF-1, rs16934386,
rs10838525 and rs3740996 in TRIM5, rs3869068 and rs8321 in
ZNRD1) were analysed in our patients. These polymorphisms
were previously studied by our group in the context of phase I
anti-HIV immunotherapy clinical trial [5]. Genotyping was per-
formed using commercially available TaqMan assays (Applied
Biosystems/AB) and ABI7500 Real-Time platform (AB). Allelic
discrimination was performed using the SDS v1.4 Software
(AB). CCR5 D32 deletion was evaluated by PCR-RFLP.2.7. Phenotypic analysisMonocytes, DC and lymphocytes were analysed for com-
mon characterization markers by flow cytometry. CD14, HLA-DR, CD11c and CD86 surface markers were used for mono-
cytes; CD11c, CD40, CD80, CD83, CD86, HLA-DR for DC;
CD3, CD38 for lymphocytes. Nonspecific IgG1, IgG2a, a
mixture of IgG1 and IgG2a were used as controls. All anti-
bodies were from BD Biosciences. Analysis was performed on
a FACSCalibur™ cell analyser (BD Biosciences) and
FLOWJO software. Data were analysed by t test or ANOVA
using GraphPad Prism software.2.8. Viability assay48 h-DC viability was evaluated by propidium iodide (PI)
staining and flow cytometry, according to manufacturer in-
struction (BD Biosciences). Analysis was performed on a
FACSCalibur™ cell analyser (BD Biosciences) and FLOWJO
software. Data were analysed by t-test using GraphPad Prism
software. Data were reported as percentage of PI negative
cells.2.9. DC-mediated T lymphocyte activationAutologous T lymphocyte activation by DC was measured
evaluating CD38 surface expression and IFN-g production.
Briefly, 2  105 autologous non-adherent PBMC were co-
cultured with 0.4  105 DC per well in a 96-well plate for
96 h. CD38 surface expression was analysed as above-
mentioned, whether IFN-g production by intracellular stain-
ing. Briefly, 20 mg/mL BrefeldinA (Sigma-Aldrich) was added
to block protein secretion for the last 4 h of the culture period.
At the end of co-culture, cells were stained for surface marker
CD3 (BD Bioscience), then permeabilized with BD Cytofix/
Cytoperm solution (BD Biosciences) and stained for intracel-
lular IFN-g (BD Biosciences). Stimulation with Staphylo-
coccal enterotoxin B (SEB) was used as positive control.
Analysis was performed on a FACSCalibur™ cell analyser
(BD Biosciences) and FLOWJO software. Data were analysed
by t-test using GraphPad Prism software.
3. Results
Gene expression of monocytes-derived dendritic cells from
6 HIVþ patients submitted to immunotherapy was examined
comparing, in each individual, 5 differentiation's steps (iDC,
4 h-DC, 14 h-DC, 24 h-DC and 48 h-DC) versus monocytes.
Clustering analysis obtained for the 6 patients on all DC
time-points showed the segregation of DC in two independent
clusters according to the donor rather than to differentiation
step or genes (group A: P1, P5 and P6; group B: P2, P3 and
P4). DC from group A presented a general down-regulation of
anti-HIV response genes, while an up-regulation was observed
in DC from group B (Fig. 1), in an apparently uniform way
along differentiation. This finding was intriguing because
HIVþ individuals selected for the clinical trial were clinically
homogeneous (seropositive for at least 5 years, absence of
anti-retroviral treatment, CD4þ >500,000, PVL>3log; see
Table 1), moreover the 6 studied patients are all males, with a
similar age and race.
Fig. 1. Clustering of genes differentially expressed during in vitro monocyte-to-DC differentiation. Heatmap reports log2FC values for 84 genes of Host anti-
HIV response gene pathway array (Qiagen) in iDC, 4 h-DC, 14 h-DC, 24 h-DC and 48 h-DC compared with monocytes. The clustering is defined by the
dendrogram on the top of the clustergram.
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looking at the available clinical data. Correlation analysis
between PVL, CD4þ and CD8þ T lymphocytes counts and
gene expression did not evidence any association with
expression profile in DC from A and B groups (data not
shown). However, taking in account the limited size of studied
individuals and the absence of clinical significant reduction of
PVL (<1 log), we can observe a higher, even not statistically
significant (p > 0.05), mean levels of T CD4þ lymphocytes
during the treatment in group A compared to B (Table 2, and
Supplementary File 1).Polymorphisms in HIV restriction factor genes (APO-
BEC3G, CCL4, CCL3, CCL5, CCR5, CUL5, CXCL12,
CXCR6, HLA-C, IFNG, PARD3B, PROX1, TRIM5, ZNRD1)
were previously evaluated in the context of immunotherapy [5]
suggesting that, at least PARD3B, appeared to be associated to
a “good” response in the phase-I clinical trial. So we consid-
ered whether HIV restriction factors could affect the immu-
notherapy out-come influencing DC biology in
HIVþ individuals. For this purpose, frequency of selected
polymorphisms in APOBEC3G, CCL4, CCL3, CCL5, CCR5,
CUL5, CXCL12, CXCR6, HLA-C, IFNG, PARD3B, PROX1,
Table 2
Difference in plasma viral load (PVL) and T CD4þ lymphocytes in HIVþ patients after anti-HIV-1 immunotherapy. Differences in log(PVL) and CD4þ
lymphocytes counts during 36-weeks follow-up were reported. Difference between group A and group B values was analysed by t test. P-values <0.05 were
considered statistically significant.
Follow-up (weeks) 2 4 6 12 24 36
DPVL (log)
Group A 0.25 0.32 0.18 0.16 0.15 0.30
Group B 0.13 0.05 0.29 0.01 0.05 0.13
t test 0.118 0.107 0.636 0.205 0.370 0.618
DCD4þ (cells/mL)
Group A 68.67 45.33 133.67 3.00 22.33 52.33
Group B 118.67 128.33 144.00 104.00 51.67 237.67
t test 0.564 0.435 0.958 0.430 0.361 0.156
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tribution did not varied in patients between group A and
group B (Supplementary File 2).
Based on clustering, we decided to analyse differential gene
expression separately in the two groups of donors, A and B.
Within the 84 genes of the RT2 Profiler PCR Array there were
at least three groups of modulated genes: genes with a p-value
<0.05 and an absolute log2FC > 2 (significantly and highly
modulated), genes with an absolute log2FC > 2 but not
significantly different (p > 0.05) and genes with a p-value
<0.05 but scarcely modulated (log2FC < 2) (Fig. 2). We
decided to considered gene expression significantly different
only when supported by a p-value <0.05 and an absolute
log2FC > 2. In Supplementary Table 3 complete gene
expression data are reported. Table 3 reports selected genes at
all the differentiation's steps according to above-mentioned
criteria. At some time points gene modulation did not reach
a statistical significant p-value, however we have included
these values (indicated with an asterisk) to emphasize that the
direction of gene modulation did not vary along differentia-
tion, neither after virus stimulation (4 h) nor after cytokines
maturation cocktail (14 h, 24 h, 48 h).
In DC from A group only few genes appeared to be
significantly and highly modulated (10 out of 84). The HIV
natural ligands CCL4 and CD4, the HIV induced transcription
factor IRF1 as well as the apoptotic genes BAD and CASP8
resulted down-regulated compared to monocytes at all the
considered time points (iDC, 4 h-DC, 14 h-DC, 24 h-DC and
48 h-DC). In a similar way, innate immune response genes,
namely IL1B, IL10, SELL, TNF and TNFSF10, also appeared
to be significantly down-regulated at least at one of the dif-
ferentiation steps.
On the other hand, in cells from group B we observed a
statistically significant modulation in 25 out of 84 genes in
quite all the considered time points. In this group, 22 genes
resulted up-regulated, whereas only 3 genes resulted down
regulated (Table 3). Genes belonging to the apoptotic as well
as to “cell activation by HIV-1” pathways were up-regulated in
these DC compared to monocytes.
Only 5 genes seemed to be significantly modulated in both
groups. IL1B and SELL were commonly down-regulated,
whereas BAD, CASP8 and IRF1 were oppositely modulated,
being down-regulated in DC from group A and up-regulated ingroup B (Table 3). This finding was not corroborated by
viability assay. Mature dendritic cells (48 h-DC) obtained
from all the patients were similarly viable (Group A: 80 ± 7%
PI-negative cells; Group B: 75 ± 4% PI-negative cells;
p ¼ 0.338), however we cannot exclude that cell death could
happen later than 48 h.
When looking at innate immune response genes (Fig. 3A),
we can observe that the expression of IL1B, IL10, SELL, TNF
and TNFSF10 was significantly down-regulated in DC
belonging to group A. However IL1B and TNF were less
down-regulated in 14 h-DC respect to the other time points,
maybe due to synergic effect of viral pulse and cytokines used
for the culture. In group B, cells significantly modulated
FCAR, IL1B, IL12B, SELL and STAT1 (Fig. 3B). Of notice,
expression of IL12B was augmented at the end of protocol,
suggesting the ability of these DC to produce IL-12, a key
cytokine in the context of immunologic synapsis.
The expression of transcription factors STAT1, IRF1 and
NF-KB has been reported to contribute to the altered suscep-
tibility to HIV infection [14], for this reason we considered
and plotted the expression profile of those genes during DC
manipulation (Fig. 3C and D), even if FC or p-value were out
of our selection criteria. It is interest to notice that whether
NFKB was weakly up-regulated in both groups, STAT1, and
IRF1 were down-regulated only in group A. As IL12 gene is a
target of IRF1, it is not surprising that only B group cells
showed up-regulation of IL12 (Fig. 3B).
Considering above-mentioned data about IL1B differential
gene expression (Fig. 3), and the key role of this cytokine in DC
biology as well as our previously reported data about the
constitutive expression of inflammasome genes in DC from
HIVþ individuals [15], we evaluated the expression of inflam-
masome’ genes NLRP3, CASP1 and IL18 in monocyte-to-DC
differentiation with a gene specific probe assay. No significant
difference inNLRP3 orCASP1modulation was observed in DC
compared to monocytes in the two groups (Fig. 4), compatible
with IL1B expression data (Fig. 3) and in accordance with our
previously published results [15]. Unexpectedly IL18 was up-
regulated in DC from group A donors, at 14 as well as at 48 h
(2.38 and 1.94-fold, respectively), but not in group B cells
(0.29 and 0.42-fold, respectively). The difference between
IL18 expression in 48 h-DC of groups A and B resulted statis-
tically significant (p < 0.05).
Fig. 2. Selection of differential expressed genes. Regulated genes in DC versus monocytes in group A (A) and B (B). Left circle represents differential expressed
genes with a p-value <0.05; right circle represents differential expressed genes with a log2FC > 2. Overlapping region represents genes with p-value<0.05 and
log2FC > 2. Circles are drowned in arbitrary scale.
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expression between the two groups of patients, we wondered
whether, before starting differentiation protocol, ex vivo pe-
ripheral blood monocytes just show a different expression
profile. For this purpose, differential gene expression was
evaluated compared group B versus group A monocytes, and
only one gene, CCR5, resulted significantly up-regulated (16-
fold, p ¼ 1.99exp-4). This data suggests that monocytes
belonging to group B could be more chronically activated [16]
and this condition could affect also the chronic activation state
of respective monocyte-derived dendritic cells, as we observed
in B group DC (Table 3).
Then we investigated whether different molecular profile
could affect dendritic cell characteristics or functionality. For
this reason we analysed by cytometry cells surface markers in
DC and monocytes as well as DC ability to activate autologous
lymphocytes in co-culture assay.
HLA-DR resulted highly expressed in the surface of
immature DC (iDC) as well as in mature DC (48 h-DC) in
both groups; this is possibly due to the chronic infection aspreviously observed in monocytes-derived DC from HIVþ
[17]. As expected, maturation and activation markers - CD40,
CD80, CD83 and CD86 e resulted significantly augmented in
mature DC compared to iDC in both groups of cells (p < 0.05)
(Fig. 5A). However, any significant difference in markers
expression between A and B groups were observed (p > 0.05),
suggesting that, at least from a phenotypic point of view, DC
from all the donors are very similar.
When looking at surface markers in ex vivo monocytes, as
the precursors of in vitro manipulated DC, monocytes from
group B donors appeared to be more activated compared to
those from group A (HLA-DR: 40% versus 57.6%; CD11c:
49.6% versus 98.2%; CD86: 48.5% versus 94.2%) (Fig. 5B),
even if this difference did not achieve significant threshold
(p > 0.05) possibly due to the limited size of samples and the
well known PBMC inter-individual heterogeneity. Wondering
whether B group patients could have all PBMC more acti-
vated, peripheral blood lymphocytes were analysed for surface
expression of activation molecule CD38, however no differ-
ences have been observed (Fig. 5C).
Table 3
Differentially expressed selected genes in groups A and B dendritic cells compared to monocytes.
Group A Group B
Genes iDC 4 h 14 h 24 h 48 h Genes iDC 4 h 14 h 24 h 48 h
HIV receptors & natural ligands
CCL5 6.86 6.45 1.25* 3.34* 3.36* CCL2 NA 2.42* 1.82* NA 4.40
CD4 0.73* 0.14* 0.77* 2.23 3.70 CXCR4 1.56* NA 2.62* 3.17* 6.05
Innate immune response
IL1B 8.88 7.35* 3.61* 7.98* 8.39* FCAR 9.97 9.30 10.31 12.83 16.89*
IL10 4.74* 3.70* 4.07* 5.86* 6.11 IL1B 2.61* 2.62* NA 1.51* 5.94
SELL 4.63* 5.12* 5.30 6.59* NA IL12B 4.18* 6.23 NA 2.07* 2.02*
TNFSF10 7.63 7.80* 7.00* 10.51* NA PRDX1 2.79 2.44* 2.68 2.99 3.33
TNF 8.59 7.56* 2.50* 6.44* 6.21* SELL NA 2.07* 1.82* 1.73* 4.32
Cellular proteins induced or activated by HIV infection
BAD 12.45 11.98 6.03 11.97 10.98 BAD 4.28 4.06 4.01 4.13 2.74*
CASP8 3.23* 2.17* 1.70 3.89 4.63* BAX 1.20* NA NA 1.02* 5.62
IRF1 7.06 5.43* 2.87* 5.04* 4.11* CASP8 2.24 2.27 1.86 2.35 1.02*
COPS6 2.19 2.15 1.96 2.04 4.41
GADD45A 2.82 2.75* 3.60 4.53 6.21
Cellular cofactors involved in HIV infection
APEX1 3.51 3.32 3.41 3.16 5.37
APOBEC3G 3.11 2.49* 2.36* 3.20 4.68
CBX5 1.62* 1.66* 1.71* 1.28* 5.54
CDK7 2.49* 2.34* 2.15* 2.59* 4.98
CDK9 1.45 NA 1.37 1.37 3.77
EP300 2.69* 2.63* 2.28 2.35* 4.86
HCK 2.93 2.55 2.87 3.15 5.66
HTATSF1 2.90 2.94 2.50 2.77 4.90
PTK2B 2.58 2.21 1.58* 2.29* 4.57
RBL2 2.31 2.18 1.69 2.14 NA
SMARCB1 2.33 2.29 2.13 2.26 2.71
TFCP2 3.15 3.03* 2.36* 3.08* 3.50
VPS4A 2.15 2.17 2.04 2.01 2.87
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to activate in vitro autologous lymphocytes, CD38 surface
expression and intracellular IFN-g were measured in lympho-
cytes from co-culture assays. CD38 expression was augmented
in B group CD3þ T cells compared to A group (21.8% versus
12.3%), however also in this case the difference was not statis-
tically significant (p > 0.05) (Fig. 6A). Intracellular IFN-g
staining revealed that DC from both groups were similarly able
to induce IFN-g production in CD3þ T cells (Fig. 6B).
Finally, to evaluate any in vivo effect of studied DC, we
compared difference (D) in PVL, CD4þ and CD8þ counts
after immunotherapy in individuals of groups A and B. Clin-
ical data have been collected before each of the three immu-
notherapy doses (t1, t2, t3) and after 1, 2 and 6 months from
the third dose (t4, t5, t6). PVL did not diminished during
treatment. Apparently group A DC induced a better CD4þ and
CD8þ (CD3þ) increment compared to group B DC
(Supplementary Table 3), however this difference was not
statistically significant at any of the time points.
4. Discussion
Liu et coll [16] have demonstrated that DC gene expression
profile could be used as a predictor of function and help the
design and/or patients selection of DC-vaccine trials in cancertherapy. With a similar purpose the differential expression of a
subset of genes involved in host anti-HIV response was ana-
lysed in dendritic cells used in the on-going Brazilian clinical
trial of anti-HIV immunotherapy.
Gene expression analysis revealed a distinct profile in
monocyte-to-DC differentiation within HIVþ individuals
submitted to immunotherapy. This profile did not apparently
correlate with initial clinical data such as CD4þ and CD8þ
cells count or plasma viral load (Table 1), nor with well-
known genetic factor involved in HIV infection pathogen-
esis, suggesting the need to investigate novel characterization
markers for DC in the contest of immunotherapy.
Cells from group B appeared to be chronically activated in
term of HIV-response, showing an up-regulation of both re-
striction and co-factors for HIV-1, but this augmented
expression did not significantly vary along differentiation,
possibly being an intrinsic characteristic of these patients
(genetic background, chronic inflammation state) and not a
consequence of dendritic cell preparation protocol. Moreover
these cells seemed to be more prone to programmed cell death
than group A, as several pro-apoptotic genes (i.e.: BAD, BAX,
CASP8) were significantly up-regulated in group B. On the
contrary, BAD and CASP8 resulted down-regulated in DC of
group A. Giri et coll [7], showed that monocytes from
HIVþ individuals are characterized by an anti-apoptotic
Fig. 3. Expression of innate immune genes during DC differentiation. Relative gene expression of selected innate immune genes in groups A and B dendritic
cells is reported during differentiation steps (iDC, 4 h-DC, 14 h-DC, 24 h-DC and 48 h-DC) compared to monocytes. IL1B, IL10, SELL, TNF and TNFSF10 are
reported for A group DC (A); FCAR, IL1B, IL12B, SELL for B group DC (B); IRF1, NF-kB and STAT1 are reported for A group DC (C) and B group DC (D).
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ported about monocyte-derived DC. We can hypothesize that
monocytes-to DC differentiation protocol may act in different
way according to original monocytes expression profile, sug-
gesting that activation state of monocytes could be taken into
account as a early predictor of DC characteristics beforeFig. 4. Expression of inflammasome genes during DC differentiation.
Relative gene expression of NLRP3, CASP1 and IL18 genes in groups A and B
dendritic cells is reported at 14 h-DC and 48 h-DC compared to monocytes.
One-way ANOVA test was used to compare A and B groups. *¼<0.05.mature DC viability result, that nowadays represents one of
the main quality control data for DC application in patients.
IRF1 expression had previously been described as a factor
that contributes to susceptibility for HIV-1 infection [14]. Our
findings evidenced a different expression modulation of this
transcription factor in the two groups of DC according with
the expression of the important Th1 driving cytokine IL-12
(Fig. 2), emphasizing once more that genomic profile could
told us a hide tale about DC functionality.
The emerging role of IL-18 in the pathogenesis of HIV
infection has been recently described, suggesting that IL-18
could be protective against HIV replication [17]. IL-18 plays
an important role in DC biology, being necessary for induction
of effector T cells [18] and memory CD8þ T cells [19].
Moreover it has been reported that in DC augmented level of
IL-18 inversely correlated with IL-10 [20], as observed also in
our results (Table 3).
In our study, possibly due to the small size of studied in-
dividuals, and we are aware of this limitation, the observed
differences in genes expression did not lead to statistically
significant differences in commonly used markers of DC
maturation, activation and in vitro ability to induced IFN-gþ T
cells.
Fig. 5. Surface activation markers analysis. (A) Phenotypic profile of
immature DC (iDC) and mature DC (48 h-DC) of A and B groups. Mean
values and standard errors (n ¼ 3) are reported. DC were analysed according
to basic characteristics of size and granulosity (not shown) and specific DC
markers (CD11c, HLADR, CD80, CD86, CD83, CD40). Two-ways ANOVA
test was used to compare iDC and 48 h-DC within each group and between A
and B groups. *¼<0.05 refers to 48 h-DC versus iDC. (B) Phenotypic profile
of ex vivo monocytes of A and B groups. Mean values and standard errors
(n ¼ 3) are reported. Monocytes were analysed according to basic charac-
teristics of size and granulosity (not shown) and specific markers (CD14,
CD11c, HLADR, CD86). One-way ANOVA test was used to compare A and B
groups. (C) Phenotypic profile of post-adherence lymphocytes of A and B
groups. Mean values and standard errors (n ¼ 3). Lymphocytes were analysed
according to basic characteristics of size and granulosity (not shown) and
specific markers (CD3, CD38). T-test was used to compare A and B groups.
Fig. 6. DC-mediated activation of autologous lymphocytes. (A) Phenotypic
profile of post-co-culture lymphocytes of A and B groups. Mean values and
standard errors (n ¼ 3) are reported. Lymphocytes were analysed according to
basic characteristics of size and granulosity (not shown) and specific markers
(CD3, CD38). T-test was used to compare A and B groups. (B) IFN-g pro-
duction in CD3þ T cells in A and B groups. Mean values (n ¼ 3) are reported.
Lymphocytes were analysed according to basic characteristics of size and
granulosity (not shown), surface marker CD3 and intracellular staining IFN-g.
T-test was used to compare A and B groups.
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All together these findings pointed out that actual criteria
for the selection of HIVþ individuals for immunotherapy
(mainly PVL, CD4þ and CD8þ counts) are not ensuring a
similar vaccine product in term of genomic activation of
monocyte-derived DC. Further investigations are needed to
elucidate the discrepancy between expression profiles in DC
from different donors.
Clinical trials generally are not designed for genetic ap-
proaches and, especially for immunotherapy, which is highly
time- and money-consuming, the number of enrolled patients
always would represent a limit. This study belongs to a larger
research work aimed to explore genetic background of
immunotherapy response and to identify predictive marker for
treatment success. We are convinced that response to DC-
based vaccine has to be considered as a multifactorial tract,
where genetic factors should be taken in account in the choice
of patients as well as in DC preparation design.Competing interests
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